INFORMATION FOR HEALTHCARE PROFESSIONALS

HER2DX logo

THE FIRST GENOMIC TOOL FOR PATIENTS WITH HER2+ BREAST CANCER

A new tool tailored for HER2+ disease
Evaluated in
>1,000 patients
HER2DX® reveals:
• long-term relapse risk
• probability of therapy response
• tumor HER2 expression levels
Image of 1 out of 5 women

1 in 5 women

with breast cancer has
HER2+ disease

World icon

> 450,000

cases diagnosed
every year worldwide

Clock image 2 minutes

Every 2 minutes

a woman is diagnosed with HER2+ breast cancer

Human Epidermal Growth Factor
Receptor-2 Positive is

one of the most
aggressive types
of breast cancer

HER2+ breast cancer is a

clinical unmet need

To date, there are no tools to predict
the beneficial effect of targeted therapy
and the risk of recurrence

A sophisticated tool
for an accurate diagnosis

HER2DX® is the first
genomic tool for patients
with early-stage HER2+
breast cancer

HER2DX® measures the expression of 27 genes
from Formalin-Fixed, Paraffin-Embedded (FFPE) breast cancer tissues.
Specifically, HER2DX® evaluates the following biological processes:

HER2DX packaging

Immune
infiltration

Luminal
differentiation

Tumor cell
proliferation

HER2
amplicon
expression

The biological information from these 4 gene signatures is combined
with clinical data such as tumor stage and nodal stage.

Luminal icon
Luminal
Proliferation of tumor icon
Proliferation
Tumor stage icon
Tumor stage
HER2 image
HER2
Immune cell icon
Immune
Nodal stage icon
Nodal stage
A line that appoints at HER2DX
HER2DX

HER2DX® has been validated in >1,000 patients

Risk Score
n=1,341

pCR Likelihood
Score
n=558

ERBB2 Score
n=353

Start your experience
with HER2DX®

REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS S.L.